[{"id":"62108e74-4662-481f-afc9-1a0b17537745","acronym":"NCI-2019-04325","url":"https://clinicaltrials.gov/study/NCT04073745","created_at":"2025-03-03T09:56:16.669Z","updated_at":"2025-03-03T09:56:16.669Z","phase":"Phase 1","brief_title":"Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04073745 - NCI-2019-04325","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • CD4 • FOXP3 • ISG20"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/04/2019","start_date":" 12/04/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-28"},{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"f2a83ef8-84cc-449b-9ded-64940f06e812","acronym":"NRG-GY002","url":"https://clinicaltrials.gov/study/NCT02257528","created_at":"2023-12-06T19:15:29.780Z","updated_at":"2025-02-25T16:36:28.321Z","phase":"Phase 2","brief_title":"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer","source_id_and_acronym":"NCT02257528 - NRG-GY002","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • PD-1 • CD4 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • PD-1 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 05/18/2015","start_date":" 05/18/2015","primary_txt":" Primary completion: 03/05/2019","primary_completion_date":" 03/05/2019","study_txt":" Completion: 03/04/2025","study_completion_date":" 03/04/2025","last_update_posted":"2025-02-06"},{"id":"c6706368-4b51-4cd8-9e6f-57a4d3ecf646","acronym":"","url":"https://clinicaltrials.gov/study/NCT01526096","created_at":"2021-01-18T06:26:01.906Z","updated_at":"2025-02-25T16:43:39.104Z","phase":"Phase 1","brief_title":"Stem Cell Transplantation for Patients With Multiple Myeloma","source_id_and_acronym":"NCT01526096","lead_sponsor":"University of Chicago","biomarkers":" IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • CD4 • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • plerixafor"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/12/2011","start_date":" 07/12/2011","primary_txt":" Primary completion: 09/12/2025","primary_completion_date":" 09/12/2025","study_txt":" Completion: 09/12/2025","study_completion_date":" 09/12/2025","last_update_posted":"2025-02-05"},{"id":"268eae36-cdca-45ae-8506-36b3e8cbd7f6","acronym":"BLAST MRD AML-2","url":"https://clinicaltrials.gov/study/NCT04284787","created_at":"2024-03-22T03:46:14.077Z","updated_at":"2025-02-25T17:00:27.213Z","phase":"Phase 2","brief_title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04284787 - BLAST MRD AML-2","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression • Chr t(15;17)","tags":["PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 06/05/2023","primary_completion_date":" 06/05/2023","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"5ba9d628-6d23-4d5d-9027-4c4a55c8330e","acronym":"NCI-2019-08626","url":"https://clinicaltrials.gov/study/NCT04214249","created_at":"2024-01-11T17:17:48.143Z","updated_at":"2025-02-25T17:00:21.915Z","phase":"Phase 2","brief_title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04214249 - NCI-2019-08626","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"7ad02231-e51d-4e77-bde9-f01924b1ddec","acronym":"PELICAN","url":"https://clinicaltrials.gov/study/NCT06232564","created_at":"2024-01-30T19:21:28.994Z","updated_at":"2025-02-25T17:32:47.858Z","phase":"Phase 2","brief_title":"A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs","source_id_and_acronym":"NCT06232564 - PELICAN","lead_sponsor":"Imperial College London","biomarkers":" PD-1 • VEGFA • CD34 • FOXP3","pipe":"","alterations":" ","tags":["PD-1 • VEGFA • CD34 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 03/02/2028","primary_completion_date":" 03/02/2028","study_txt":" Completion: 08/02/2028","study_completion_date":" 08/02/2028","last_update_posted":"2025-01-30"},{"id":"9c6947a9-7642-44d7-8cde-da7fb3ca0beb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05586360","created_at":"2022-10-19T13:56:32.222Z","updated_at":"2025-02-25T17:31:39.005Z","phase":"Phase 2","brief_title":"T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer","source_id_and_acronym":"NCT05586360","lead_sponsor":"Medical University of South Carolina","biomarkers":" FOXP3","pipe":"","alterations":" ","tags":["FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-30"},{"id":"44b80189-528f-4f15-a751-b2fa0ad145eb","acronym":"PCR-MIB","url":"https://clinicaltrials.gov/study/NCT02662062","created_at":"2025-02-25T18:11:21.641Z","updated_at":"2025-02-25T18:11:21.641Z","phase":"Phase 2","brief_title":"Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02662062 - PCR-MIB","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","biomarkers":" CD20 • CD8 • PD-1 • LAG3 • CD4 • ICOS • FOXP3","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD8 • PD-1 • LAG3 • CD4 • ICOS • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/11/2017","start_date":" 07/11/2017","primary_txt":" Primary completion: 05/12/2022","primary_completion_date":" 05/12/2022","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2025-01-27"},{"id":"53f4eddd-132e-4531-8be4-d3f2264f7d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT06790797","created_at":"2025-02-25T18:39:59.893Z","updated_at":"2025-02-25T18:39:59.893Z","phase":"","brief_title":"Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients","source_id_and_acronym":"NCT06790797","lead_sponsor":"Zhao Jun","biomarkers":" CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/12/2023","start_date":" 02/12/2023","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-01-24"},{"id":"ec81dee1-ccab-428c-9718-7a66b69c4ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT06743503","created_at":"2025-02-26T07:40:37.187Z","updated_at":"2025-02-26T07:40:37.187Z","phase":"Phase 1","brief_title":"UB-VV400 in Combination with Rapamycin in Relapsed or Refractory B-cell Malignancies","source_id_and_acronym":"NCT06743503","lead_sponsor":"Nanjing IASO Biotechnology Co., Ltd.","biomarkers":" CD20 • CD8 • CD4 • NCAM1 • FOXP3","pipe":"","alterations":" ","tags":["CD20 • CD8 • CD4 • NCAM1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/31/2024","start_date":" 12/31/2024","primary_txt":" Primary completion: 05/21/2028","primary_completion_date":" 05/21/2028","study_txt":" Completion: 07/31/2030","study_completion_date":" 07/31/2030","last_update_posted":"2024-12-20"},{"id":"10e7c484-a234-4aa3-b3ff-69b3ed1da252","acronym":"CA209-324","url":"https://clinicaltrials.gov/study/NCT02648997","created_at":"2024-01-24T15:18:16.455Z","updated_at":"2025-02-25T14:36:04.275Z","phase":"Phase 2","brief_title":"An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma","source_id_and_acronym":"NCT02648997 - CA209-324","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PD-L1 • PD-1 • IL2RA • CD4 • CD69 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1 • IL2RA • CD4 • CD69 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-19"},{"id":"8786017d-2cf8-4ded-8bf4-82944af9b864","acronym":"COLIBRI","url":"https://clinicaltrials.gov/study/NCT04256213","created_at":"2021-01-18T20:41:17.978Z","updated_at":"2025-02-25T14:29:01.637Z","phase":"","brief_title":"COL Immunotherapy Before Radiochimio + Ipilimumab","source_id_and_acronym":"NCT04256213 - COLIBRI","lead_sponsor":"ARCAGY/ GINECO GROUP","biomarkers":" FOXP3","pipe":"","alterations":" ","tags":["FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 08/04/2024","study_completion_date":" 08/04/2024","last_update_posted":"2024-12-12"},{"id":"9b80d640-ac33-4411-ad4d-9614359a1e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT02265536","created_at":"2025-07-19T14:00:09.317Z","updated_at":"2025-07-19T14:00:09.317Z","phase":"Phase 1","brief_title":"A Study of LY3022855 In Participants With Breast or Prostate Cancer","source_id_and_acronym":"NCT02265536","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 11/03/2017","study_completion_date":" 11/03/2017","last_update_posted":"2024-10-28"},{"id":"7d9b53ef-b645-44ee-9c8e-8c8c3875b0f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06569485","created_at":"2025-02-26T12:22:38.642Z","updated_at":"2025-02-26T12:22:38.642Z","phase":"Phase 2","brief_title":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients","source_id_and_acronym":"NCT06569485","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD8 • IFNG • CDK4 • IL2RA • CD4 • IL2 • FOXP3 • IL17A • ISG20","pipe":"","alterations":" ","tags":["CD8 • IFNG • CDK4 • IL2RA • CD4 • IL2 • FOXP3 • IL17A • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 05/23/2024","start_date":" 05/23/2024","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-08-26"},{"id":"4f28ce0c-9a5a-4a61-b5dd-312c3d0839fe","acronym":"KEYNOTE-A10","url":"https://clinicaltrials.gov/study/NCT03058289","created_at":"2021-01-18T15:03:51.688Z","updated_at":"2025-02-25T14:37:17.876Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","source_id_and_acronym":"NCT03058289 - KEYNOTE-A10","lead_sponsor":"Intensity Therapeutics, Inc.","biomarkers":" MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2024-08-13"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"23dbdc8e-972e-4762-87c9-f40d67d274d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05080946","created_at":"2021-10-18T12:53:00.791Z","updated_at":"2024-07-02T16:34:26.049Z","phase":"Phase 1","brief_title":"Using Aspirin to Improve Immunological Features of Ovarian Tumors","source_id_and_acronym":"NCT05080946","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD163 • FOXP3","pipe":"","alterations":" ","tags":["CD163 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-14"},{"id":"2ad87160-49d5-4bc4-8098-f9a7728e8b68","acronym":"NCI-2017-01387","url":"https://clinicaltrials.gov/study/NCT02451423","created_at":"2021-01-18T11:45:12.347Z","updated_at":"2024-07-02T16:34:59.633Z","phase":"Phase 2","brief_title":"Neoadjuvant Atezolizumab in Localized Bladder Cancer","source_id_and_acronym":"NCT02451423 - NCI-2017-01387","lead_sponsor":"Lawrence Fong","biomarkers":" PD-L1 • CD8 • CD4 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 03/29/2016","start_date":" 03/29/2016","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2024-05-31"},{"id":"7751beea-ed0b-4a4d-8397-acffe8af0a14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432378","created_at":"2021-01-18T11:38:27.441Z","updated_at":"2024-07-02T16:35:00.114Z","phase":"Phase 1/2","brief_title":"Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","source_id_and_acronym":"NCT02432378","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX","pipe":"","alterations":" ","tags":["IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Suspended","enrollment":" Enrollment 25","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-30"},{"id":"4ddeafce-3b8e-4b29-b230-0788f469d7b7","acronym":"PRORECT","url":"https://clinicaltrials.gov/study/NCT04525989","created_at":"2024-03-05T21:32:32.859Z","updated_at":"2024-07-02T16:35:02.544Z","phase":"","brief_title":"Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)","source_id_and_acronym":"NCT04525989 - PRORECT","lead_sponsor":"Alexander Valdman","biomarkers":" CEACAM5 • FOXP3","pipe":"","alterations":" ","tags":["CEACAM5 • FOXP3"],"overall_status":"Recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-05-20"},{"id":"8e76549d-af11-4f1e-8e81-eb9a8a62b421","acronym":"NCI-2017-01950","url":"https://clinicaltrials.gov/study/NCT03348748","created_at":"2024-05-11T04:28:26.434Z","updated_at":"2024-07-02T16:35:05.635Z","phase":"Phase 1","brief_title":"Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03348748 - NCI-2017-01950","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8 • IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • IL2RA • CD4 • FOXP3 • ISG20"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/18/2017","start_date":" 12/18/2017","primary_txt":" Primary completion: 07/12/2021","primary_completion_date":" 07/12/2021","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2024-05-07"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"75cf148e-b887-4424-83a5-20bddaa84fcb","acronym":"FRAIL-IMMUNE","url":"https://clinicaltrials.gov/study/NCT03723967","created_at":"2024-04-22T19:24:32.939Z","updated_at":"2024-07-02T16:35:08.471Z","phase":"Phase 2","brief_title":"FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel","source_id_and_acronym":"NCT03723967 - FRAIL-IMMUNE","lead_sponsor":"Centre Leon Berard","biomarkers":" CD20 • CD8 • CD38 • CD4 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD20 • CD8 • CD38 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 05/16/2020","primary_completion_date":" 05/16/2020","study_txt":" Completion: 03/09/2024","study_completion_date":" 03/09/2024","last_update_posted":"2024-04-22"}]